<a href="https://www.fiercebiotech.com/biotech/asco-kelonia-keeps-vivo-car-t-momentum-rolling-nutty-100-response-rate" hreflang="en">ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout</a>
Kelonia Therapeutics presented impressive data at ASCO 2026, showing a 100% response rate in 18 patients with relapsed or refractory multiple myeloma treated with their in vivo CAR-T therapy, KLN-1010, which helped justify Eli Lilly's $3.2 billion acquisition of the company. The treatment demonstrated complete cancer eradication and a favorable safety profile, prompting plans for further clinical trials and potential applications in other cancers.
The most valuable insight for you is the potential of in vivo CAR-T therapies demonstrated by Kelonia Therapeutics' KLN-1010, which showed a 100% response rate in treating relapsed or refractory multiple myeloma with a strong safety profile. This highlights a promising investment and development opportunity in the healthtech and biotech sectors, particularly in scalable and innovative cell therapy approaches, as Eli Lilly's acquisition indicates a strategic move to capitalize on this advanced therapeutic modality.